Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 4/20 | 0.44 |
| ▸ | TERT | O14746 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 3/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490856 | 0.94 | HRH2 (0.46) | DNM2HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL88878 | 0.89 | CNR2 (0.49) | DNM2TERTCNR2ALDH1A1MAPT | |
| SCHEMBL1072521 | 0.88 | DNM2 (0.53) | DNM2CNR2CDC25AICMTALDH1A1 | |
| SCHEMBL8262776 | 0.86 | CNR2 (0.48) | DNM2TERTCNR2CDC25AICMT | |
| SCHEMBL27854488 | 0.85 | DNM2 (0.46) | DNM2CNR2CDC25AICMT | |
| SCHEMBL13132369 | 0.85 | CNR2 (0.47) | DNM2TERTCNR2ALDH1A1MAPT | |
| SCHEMBL1518736 | 0.84 | CNR2 (0.47) | CNR2NPSR1KDM4E | |
| SCHEMBL16977262 | 0.83 | DNM2 (0.46) | DNM2TERTCNR2CDC25AICMT | |
| SCHEMBL8263899 | 0.83 | CNR1 (0.46) | DNM2TERTCNR2CDC25AICMT | |
| SCHEMBL13490794 | 0.82 | CDC25A (0.51) | DNM2CNR2HRH2CDC25AICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2300453-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2274295-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-01-19 | — | — | EP | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2009140769-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009140769-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | DNM2 1342/4885TERT 1985/4885CNR2 2560/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | DNM2 3256/4885TERT 1008/4885CNR2 2478/4885 |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, AGTR1 | DNM2 1626/4885TERT 1341/4885CNR2 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.